Hepalink(SZ:002399)2023-03-29 16:00Dividend Distribution - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares to all shareholders, based on a total of 1,467,296,204 shares[4]. - The company distributed a cash dividend of 0.35 yuan per 10 shares based on a total share capital of 1,467,296,204 shares, approved at the 2021 annual general meeting[92]. - The cash dividend policy complies with the company's articles of association and has been transparently executed[93]. Financial Performance - The company reported a revenue of RMB 1.5 billion for the fiscal year 2022, representing a year-over-year growth of 15%[39]. - The company's total revenue for 2022 was RMB 7,159,410,684.41, primarily from the production and sales of heparin raw materials and formulations, as well as contract development and manufacturing organization (CDMO) services[113]. - The net profit for the year reached CNY 714,687,211.31, a significant increase compared to CNY 233,383,425.18 from the previous year, representing a growth of about 206.5%[191]. - The company's operating profit improved to CNY 828,623,184.85, up from CNY 227,474,697.78, marking an increase of around 264.5%[191]. - The company reported a decrease in accounts payable from CNY 171,477,883.69 to CNY 99,991,386.43, a reduction of about 41.7%[187]. - The total liabilities reached CNY 8,406.56 million, compared to CNY 7,584.86 million in the previous period, marking an increase of approximately 10.8%[183]. Future Guidance and Growth - The company has set a revenue guidance for 2023 at RMB 1.8 billion, indicating a projected growth of 20%[39]. - User data showed an increase in active users by 20% to 2 million in the same period[39]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[46]. - New product development includes a breakthrough in monoclonal antibody technology, expected to launch in Q3 2023[46]. Compliance and Governance - The company has maintained its commitment to transparency, with all financial reports signed and stamped by responsible parties[24]. - The company retained Ernst & Young Hua Ming as the domestic auditor for the 2022 financial report, with total audit fees amounting to RMB 5.58 million and internal control audit fees of RMB 0.43 million[54]. - The audit committee reviewed and agreed on the annual financial reports and internal control evaluations for 2021[153]. - The company has established a series of plans to ensure timely and full repayment of its bonds, including dedicated departments and personnel, and strict execution of financial management plans[88]. Employee and Management Information - The total number of employees at the end of the reporting period was 2,366, with 936 in the parent company and 1,430 in major subsidiaries[158]. - The company has established a competitive salary system based on performance and capability, ensuring fair compensation across different positions[158]. - Total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 1,396.48 million[176]. Risk Management - The company has detailed its future risks and countermeasures in the annual report, highlighting the importance of investor awareness regarding investment risks[19]. - The company has not reported any changes in its main business operations since its listing[32]. - The company has not reported any major matters that require explanation during the reporting period[65]. Financial Health Indicators - The company's EBITDA to total debt ratio improved to 21.40%, an increase of 8.47% compared to the previous year[106]. - The current ratio decreased by 1.14% to 2.222, while the quick ratio dropped by 21.39% to 0.9946[106]. - The debt-to-asset ratio increased to 40.39%, up by 0.70% from the previous year[106]. - Interest coverage ratio improved significantly to 4.53, a 115.71% increase from 2.10 in the previous year[130]. Asset and Liability Management - The total assets increased to CNY 14,483,308,913.97 from CNY 14,324,415,709.31, reflecting a growth of approximately 1.11%[187]. - Non-current liabilities totaled CNY 2,830.77 million, slightly up from CNY 2,793.39 million, indicating a growth of about 1.3%[183]. - The company's capital reserve decreased to CNY 5,858.62 million from CNY 5,943.65 million, a decline of about 1.4%[183]. Strategic Investments - The company has invested RMB 200 million in sustainable practices, aiming for a 30% reduction in waste emissions by 2025[46]. - The company has established partnerships with leading technology firms to enhance its production processes and product offerings[46]. - The company has made strategic investments in new product development and technology, although specific figures are not provided in the content[194].